Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Impulse Control Disorders associated with Pramipexole/Ropinirole Use in Non-Parkinson's Disease: A Scoping Review

파킨슨 병 이외의 적응증을 가진 환자의 Pramipexole 혹은 Ropinirole 사용과 관련된 충동 조절 장애: 주제 범위 문헌 고찰

  • Jeong, Tae hyun (Chonnam National University College of Pharmacy) ;
  • Suh, Seoung Min (Chonnam National University College of Pharmacy) ;
  • Song, Hyun Jin (University of Florida College of Pharmacy Department of Pharmaceutical Outcomes and Policy) ;
  • Jeon, Nakyung (Chonnam National University College of Pharmacy)
  • Received : 2020.10.24
  • Accepted : 2020.12.10
  • Published : 2020.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Dopamine receptor agonists (DRAs) have been associated with impulse control disorders (ICDs) in Parkinson's disease (PD) in preliminary studies. Whether the association holds true when DRAs are used to treat non-PD, such as restless legs syndrome, prolactinoma, and several mood disorders is uncertain. Objective: The present study aimed to understand the research gaps related to the risk of ICDs associated with pramipexole or ropinirole (PRX/ROP) use as a treatment for specific underlying diseases, excluding Parkinson's disorders. Methods: We conducted a scoping review, systematically searching databases to identify literature on the types, prevalence, and factors associated with ICD in non-PD patients receiving PRX/ROP. All relevant information that helped understand the epidemiology of ICDs among non-PD patients taking PRX/ROP were extracted and analyzed. We also evaluated the potential associations between PRX/ROP and ICDs, utilizing the Naranjo scale or statistical analysis, depending on the type of literature. Results: We included 24 articles (19 case reports or case series and 5 population-based studies) in this scoping review. Evaluating the 19 case reports or case series using Naranjo scores led to the discovery of a possible link between PRX/ROP exposure and ICDs. However, important information to assess causality is frequently missing. Moreover, the population-based studies lack diversity in the study populations and enough study samples to draw conclusive results. Conclusion: Our scoping review suggests that the currently available literature requires more details in future case reports and for well-powered studies in various disease conditions where PRX/ROP is frequently used.

Keywords

References

  1. Kim J, Yu Y. A psychological approach on impulse control disorder criminal. Korean Crim Psychol Rev 2015;11(3):53-76.
  2. Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne EJ, Burns A. Carer burden in apathy and impulse control disorders in Parkinson's disease. Int J Geriatr Psychiatry 2012;27(2):160-6. https://doi.org/10.1002/gps.2704
  3. Callesen MB, Scheel-Kruger J, Kringelbach ML, Moller A. A systematic review of impulse control disorders in Parkinson's disease. J Parkinsons Dis 2013;3(2):105-38. https://doi.org/10.3233/JPD-120165
  4. Molde H, Moussavi Y, Kopperud ST, Erga AH, Hansen AL, Pallesen S. Impulse-control disorders in Parkinson's disease: a meta-analysis and review of case-control studies. Front Neurol 2018;9:330. https://doi.org/10.3389/fneur.2018.00330
  5. Gatto EM, Aldinio V. Impulse control disorders in Parkinson's disease. A brief and comprehensive review. Front Neurol 2019;10:351. https://doi.org/10.3389/fneur.2019.00351
  6. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63(7):969-73. https://doi.org/10.1001/archneur.63.7.969
  7. Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 2015;69(4):183-9. https://doi.org/10.1002/syn.21805
  8. Rizos A, Sauerbier A, Antonini A, et al. A european multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 2016;23(8):1255-61. https://doi.org/10.1111/ene.13034
  9. Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, et al. Dopamine agonists and impulse control disorders: A complex association. Drug Saf 2018;41(1):19-75. https://doi.org/10.1007/s40264-017-0590-6
  10. Schreiber L, Odlaug BL, Grant JE. Impulse control disorders: updated review of clinical characteristics and pharmacological management. Front psychiatry. 2011;2:1. https://doi.org/10.3389/fpsyt.2011.00001
  11. Ohayon MM, O'Hara R, Vitiello MV. Epidemiology of restless legs syndrome: A synthesis of the literature. Sleep Med Rev 2012;16(4):283-95. https://doi.org/10.1016/j.smrv.2011.05.002
  12. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005;8(1):3-6. https://doi.org/10.1007/s11102-005-5079-0
  13. Sucharew H, Macaluso M. Methods for research evidence synthesis: The scoping review approach. J Hosp Med 2019;14(7):416-8. https://doi.org/10.12788/jhm.3248
  14. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005;8(1):19-32. https://doi.org/10.1080/1364557032000119616
  15. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45. https://doi.org/10.1038/clpt.1981.154
  16. Voon V, Schoerling A, Wenzel S, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol 2011;11(1):117. https://doi.org/10.1186/1471-2377-11-117
  17. Bayard S, Langenier MC, Dauvilliers Y. Decision-making, rewardseeking behaviors and dopamine agonist therapy in restless legs syndrome. Sleep 2013;36(10):1501-7. https://doi.org/10.5665/sleep.3044
  18. Heim B, Djamshidian A, Heidbreder A, et al. Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association? Neurology 2016;87(1):36-40. https://doi.org/10.1212/WNL.0000000000002803
  19. Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med 2011;12(1):34-40. https://doi.org/10.1016/j.sleep.2010.08.005
  20. Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med 2012;13(10):1280-5. https://doi.org/10.1016/j.sleep.2012.08.004
  21. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med 2018;169(7):467-73. https://doi.org/10.7326/m18-0850
  22. Leeman RF, Potenza MN. Impulse control disorders in Parkinson's disease: clinical characteristics and implications. Neuropsychiatry (London) 2011;1(2):133-47. https://doi.org/10.2217/npy.11.11
  23. Kolla BP, Mansukhani MP, Barraza R, Bostwick JM. Impact of dopamine agonists on compulsive behaviors: A case series of pramipexole-induced pathological gambling. Psychosomatics 2010;51(3):271-3. https://doi.org/10.1016/S0033-3182(10)70695-2
  24. Driver-Dunckley ED, Noble BN, Hentz JG, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007;30(5):249-55. https://doi.org/10.1097/wnf.0b013e31804c780e
  25. Cornelinus J. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010;33(1):81-7.
  26. Mishima T, Fujioka S, Kurisaki R, et al. Impulse control disorders and punding in Perry syndrome. Parkinsonism Relat Disord 2015;21(11):1381-2. https://doi.org/10.1016/j.parkreldis.2015.09.037
  27. Tajima-Pozo K, Bardudo E, Aguilar-Shea AL, Papanti D. Paraphilia as adverse drug reaction to dopamine agonist (Pramipexole). Acta Neuropsychiatr 2011;23(2):89.
  28. Strejilevich SA, Martino DJ, Igoa A, Manes F. Pathological gambling in a bipolar patient treated with pramipexole. J Neuropsychiatry Clin Neurosci 2011;23(1)E2-3.
  29. Maruo J, Haraguchi Y, Tateishi H, et al. Abnormal behaviours during pramipexole treatment for Cotard's syndrome: a case report. Psychogeriatrics 2016;16(4):283-6. https://doi.org/10.1111/psyg.12148
  30. Larson ER. Neuropsychological findings in a case of punding before and after cessation of pramipexole. Clin Neuropsychol 2015;29(1):166-78. https://doi.org/10.1080/13854046.2015.1005674
  31. Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018;91(3):e189-201. https://doi.org/10.1212/wnl.0000000000005816
  32. Lizarraga KJ, Fox SH, Strafella AP, Lang AE. Hallucinations, delusions and impulse control disorders in Parkinson disease. Clin Geriatr Med 2019;36(1):105-18.